Elanco

Elanco, established in 1954, stands as a cornerstone of the global animal health industry. The company specializes in the research, development, manufacturing, and commercialization of advanced pharmaceutical products, vaccines, and antibiotics tailored for both companion animals and food-producing livestock. By prioritizing veterinary medicine and sustainable animal health solutions, Elanco maintains a robust, science-driven portfolio designed to significantly improve animal welfare, disease prevention, and agricultural productivity across diverse international markets. Their commitment to innovation ensures they remain at the forefront of the evolving veterinary sector.

Operating with a significant global footprint, Elanco manages 42 distinct locations worldwide to support its extensive research, development, and distribution networks. The company currently sustains a workforce of 5,000-10,000 employees who are dedicated to driving technological innovation and operational excellence in animal health. Learn about Elanco's global headquarters for detailed information regarding their primary operational hub in Greenfield, Indiana, and their broader geographic presence. This strategic infrastructure allows the firm to effectively serve veterinary professionals and pet owners across multiple continents, ensuring consistent delivery of high-quality medical solutions.

With annual revenue reaching $5.0B, Elanco remains a formidable competitor against major industry players such as Zoetis and Covetrus. The company continues to leverage its strong market position to advance its proprietary innovation platform and expand its veterinary medicine offerings. Meet Elanco's team to explore their leadership structure and organizational expertise, or Explore financial highlights for a comprehensive overview of their fiscal performance, debt financing, and long-term growth strategy. Through these initiatives, Elanco maintains its status as a leader inView more...